Graham Capital Management L.P. Invests $731,000 in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Graham Capital Management L.P. acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 97,257 shares of the biotechnology company's stock, valued at approximately $731,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after acquiring an additional 1,583,826 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in shares of BioCryst Pharmaceuticals by 25.1% during the 4th quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company's stock valued at $438,000 after purchasing an additional 11,711 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in BioCryst Pharmaceuticals by 4.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock worth $14,890,000 after purchasing an additional 91,998 shares in the last quarter. Raymond James Financial Inc. bought a new position in BioCryst Pharmaceuticals in the 4th quarter valued at approximately $80,000. Finally, Choreo LLC acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $106,000. Institutional investors own 85.88% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BCRX. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. JPMorgan Chase & Co. boosted their price objective on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Wedbush began coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 target price for the company. JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, StockNews.com downgraded shares of BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.56.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX opened at $9.85 on Thursday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $5.90 and a 52 week high of $11.11. The firm's fifty day moving average is $8.00 and its 200-day moving average is $7.93. The firm has a market cap of $2.06 billion, a P/E ratio of -16.15 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same quarter in the prior year, the business earned $0.28 earnings per share. The company's revenue was up 40.8% on a year-over-year basis. As a group, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.